TONIX PHARMACEUTICALS HOLDING CORP. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $1.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-08-10
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-06-30 was $1.05M, a 115.40% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-03-31 was $676.00K, a 69.02% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-06-30 was $487.00K, a 71.42% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-03-31 was $2.18M.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $2.26M.
- TONIX PHARMACEUTICALS HOLDING CORP. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2016 was $280.00K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 1 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 9 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.05M 10-Q · filed 2026-08-10 | $1.73M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $676.00K 10-Q · filed 2026-08-10 | ||||
| 2025-06-30 | $487.00K 10-Q · filed 2026-08-10 | $2.67M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $2.18M 10-Q · filed 2026-08-10 | ||||
| 2024-12-31 | $2.26M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $557.00K 10-Q · filed 2025-11-10 | $2.26M derived: sum of 2 quarters · filed 2025-11-10 | |||
| 2024-06-30 | $1.70M 10-Q · filed 2025-11-10 | ||||
| 2023-09-30 | $726.00K 10-Q · filed 2023-11-09 | $762.00K derived: sum of 2 quarters · filed 2024-11-12 | $863.00K derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $36.00K 10-Q · filed 2024-11-12 | $137.00K derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $101.00K 10-Q · filed 2024-11-12 | ||||
| 2022-09-30 | $805.00K 10-Q · filed 2023-11-09 | $2.23M derived: sum of 2 quarters · filed 2023-11-09 | $2.74M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $1.43M 10-Q · filed 2023-11-09 | $1.93M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $507.00K 10-Q · filed 2023-11-09 | ||||
| 2019-06-30 | $1.00K 10-Q · filed 2020-11-09 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $45.00K 10-Q · filed 2018-11-09 | ||
| 2018-06-30 | $50.00K 10-Q · filed 2018-08-13 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $45.00K 10-Q · filed 2018-08-13 | ||
| 2018-03-31 | $45.00K 10-Q · filed 2018-05-11 | ||||
| 2017-10-31 | $15.00K 10-K · filed 2018-03-09 | ||||
| 2017-06-30 | $245.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $280.00K 10-Q · filed 2017-08-11 | |||
| 2017-04-30 | $888.00K 10-K · filed 2018-03-09 | $280.00K 10-K · filed 2018-03-09 | |||
| 2017-03-31 | $35.00K 10-Q · filed 2017-05-12 | $166.00K derived: sum of 2 quarters · filed 2017-05-12 | $166.00K derived: sum of 3 quarters · filed 2017-05-12 | ||
| 2016-12-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-13 | $131.00K derived: sum of 2 quarters · filed 2017-04-13 | $280.00K 10-K · filed 2017-04-13 | ||
| 2016-10-31 | $585.00K 10-K · filed 2018-03-09 | $280.00K 10-K · filed 2018-03-09 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $149.00K 10-Q · filed 2016-11-10 | |||
| 2016-07-31 | $105.00K 10-K · filed 2018-03-09 | ||||
| 2016-06-30 | $916.00K 10-K · filed 2018-03-09 | $149.00K 10-Q · filed 2016-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |